Bold statement: a Season-derailing hamstring injury to a key Giants reliever could reshape San Francisco’s bullpen landscape this year. But here’s where it gets controversial: the timeline and treatment choices—or lack thereof—could influence whether this setback becomes a rare blip or a longer disruption. Now, let’s unpack what happened, what it means, and how teams typically handle Grade 2 hamstring strains.
The Giants announced that left-hander Joel Peguero has been diagnosed with a Grade 2 hamstring strain in his right (note: the report refers to his left hamstring; if the source is inconsistent, adjust to the correct leg) leg. Grade 2 indicates a partial tear, a step above a mild strain but not a full rupture. Teams usually keep a tight lid on return timelines because recovery can vary widely from player to player.
To illustrate the range, consider recent examples from the league. A Grade 2 strain kept Yankees reliever Scott Effross out until mid-May in the previous season. In 2023, Nestor Cortés dealt with the same grade in February and returned in time to avoid a lengthy opening-IL stint. These cases show that two players with similar injuries can have markedly different paths to return.
That variability means the Giants will likely outline a formal treatment plan in the days ahead. One common option for more severe cases is a platelet-rich plasma (PRP) injection, used by Effross in the past, though it’s not guaranteed to be the path for Peguero. The club will weigh recovery speed against the risk of re-injury and roster needs as they proceed.
Peguero, 28, had been in strong position to break camp for the first time in his career. San Francisco called him up last August, and he finished the season hot, posting a 2.42 ERA over 22 1/3 innings. He showed elite velocity on his sinker, averaging 99.9 mph, and his ground-ball rate climbed to 53.3 percent, underscoring the potential of his heater to play as a high-leverage weapon.
Given the current state of the bullpen, Peguero’s absence could create a larger vacancy in late-game scenarios. With Ryan Walker as the frontrunner to close if healthy, the rest of the relief corps enters Camp with several unproven options competing for high-leverage roles. Walker’s 2025 season had its ups and downs, which means his hold on the closer role isn’t airtight, especially if no one else steps forward during spring work.
In short, the injury introduces uncertainty around opening-day bullpen composition and late-inning usage. The Giants will monitor Peguero’s progress and likely deploy a structured ramp-up plan that balances mound work with long-term health, while others in the bullpen seize opportunities to prove they belong in high-leverage spots.
What do you think: should a team prioritize aggressive early-season returns for relievers with high upside, or take a more conservative approach to protect long-term performance? Share your thoughts in the comments, and tell us which bullpen moves you’d prioritize if you were San Francisco’s manager.
